ValuEngine cut shares of NovaBay Pharmaceuticals, Inc. (NYSEMKT:NBY) from a hold rating to a sell rating in a research note released on Friday, September 1st.
Separately, Roth Capital reiterated a buy rating and issued a $5.50 target price on shares of NovaBay Pharmaceuticals in a research note on Monday, June 5th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company. NovaBay Pharmaceuticals has a consensus rating of Hold and an average target price of $7.17.
NovaBay Pharmaceuticals (NYSEMKT NBY) opened at 4.35 on Friday. The company has a 50-day moving average of $4.42 and a 200 day moving average of $3.70. The firm’s market cap is $66.59 million. NovaBay Pharmaceuticals has a 52-week low of $2.25 and a 52-week high of $5.09.
About NovaBay Pharmaceuticals
NovaBay Pharmaceuticals, Inc, formerly NovaCal Pharmaceuticals, Inc, is a biopharmaceutical company, which develops products for the eye care market. The Company focuses on commercializing prescription Avenova for managing hygiene of the eyelids and lashes in the United States. Avenova is an eye care product formulated with a form of hypochlorous acid called Neutrox.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for NovaBay Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NovaBay Pharmaceuticals Inc. and related companies with our FREE daily email newsletter.